CNS Pharmaceuticals (CNSP) Competitors

$5.01 -0.51 (-9.24%)

Closing price 05/14/2026 04:00 PM Eastern

Extended Trading

$5.11 +0.10 (+2.02%)

As of 08:16 AM Eastern

CNSP vs. PTPI, XCUR, TRAW, QNCX, and KTTA

Should you buy CNS Pharmaceuticals stock or one of its competitors? MarketBeat compares CNS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with CNS Pharmaceuticals include Petros Pharmaceuticals (PTPI), Exicure (XCUR), Traws Pharma (TRAW), Quince Therapeutics (QNCX), and Pasithea Therapeutics (KTTA). These companies are all part of the "pharmaceutical products" industry.

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

CNS Pharmaceuticals (NASDAQ:CNSP) and Petros Pharmaceuticals (NASDAQ:PTPI) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 12.3% of Petros Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

In the previous week, CNS Pharmaceuticals had 3 more articles in the media than Petros Pharmaceuticals. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 0 mentions for Petros Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.06 beat Petros Pharmaceuticals' score of 0.00 indicating that CNS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Petros Pharmaceuticals	Neutral

CNS Pharmaceuticals currently has a consensus price target of $20.00, suggesting a potential upside of 299.20%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe CNS Pharmaceuticals is more favorable than Petros Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Petros Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

CNS Pharmaceuticals has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market. Comparatively, Petros Pharmaceuticals has a beta of 1.91, suggesting that its stock price is 91% more volatile than the broader market.

Petros Pharmaceuticals has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Petros Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$41.30	N/A
Petros Pharmaceuticals	$5.11M	0.04	-$8.16M	-$10.07	N/A

Petros Pharmaceuticals' return on equity of -78.22% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-164.56%	-130.05%
Petros Pharmaceuticals	N/A	-78.22%	-23.50%

Summary

CNS Pharmaceuticals and Petros Pharmaceuticals tied by winning 7 of the 14 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Exicure?

Exicure (NASDAQ:XCUR) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, dividends, media sentiment, risk, valuation, profitability, analyst recommendations and institutional ownership.

In the previous week, CNS Pharmaceuticals had 1 more articles in the media than Exicure. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 2 mentions for Exicure. CNS Pharmaceuticals' average media sentiment score of 1.06 beat Exicure's score of 0.93 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CNS Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Exicure is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exicure	N/A	N/A	-$4.95M	-$0.77	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$41.30	N/A

CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 299.20%. Given CNS Pharmaceuticals' stronger consensus rating and higher possible upside, analysts clearly believe CNS Pharmaceuticals is more favorable than Exicure.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

42.8% of Exicure shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 52.8% of Exicure shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Exicure's return on equity of -138.71% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exicure	N/A	-138.71%	-62.76%
CNS Pharmaceuticals	N/A	-164.56%	-130.05%

Exicure has a beta of 3.62, indicating that its share price is 262% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market.

Summary

Exicure beats CNS Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Traws Pharma?

Traws Pharma (NASDAQ:TRAW) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, Traws Pharma had 5 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 8 mentions for Traws Pharma and 3 mentions for CNS Pharmaceuticals. CNS Pharmaceuticals' average media sentiment score of 1.06 beat Traws Pharma's score of 0.70 indicating that CNS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Traws Pharma	2 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CNS Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Traws Pharma has higher revenue and earnings than CNS Pharmaceuticals. CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Traws Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Traws Pharma	$2.79M	5.94	$9.17M	$0.93	1.75
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$41.30	N/A

Traws Pharma presently has a consensus price target of $8.00, suggesting a potential upside of 390.80%. CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 299.20%. Given Traws Pharma's stronger consensus rating and higher probable upside, equities research analysts plainly believe Traws Pharma is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Traws Pharma	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

8.0% of Traws Pharma shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 14.0% of Traws Pharma shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Traws Pharma has a beta of 1.47, suggesting that its stock price is 47% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market.

Traws Pharma's return on equity of 112.18% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Traws Pharma	N/A	112.18%	35.31%
CNS Pharmaceuticals	N/A	-164.56%	-130.05%

Summary

Traws Pharma beats CNS Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, dividends, risk, media sentiment, profitability, analyst recommendations and institutional ownership.

In the previous week, Quince Therapeutics had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 4 mentions for Quince Therapeutics and 3 mentions for CNS Pharmaceuticals. Quince Therapeutics' average media sentiment score of 1.35 beat CNS Pharmaceuticals' score of 1.06 indicating that Quince Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
CNS Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Quince Therapeutics has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 2.62, suggesting that its stock price is 162% more volatile than the broader market.

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than Quince Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$41.30	N/A

30.8% of Quince Therapeutics shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 20.3% of Quince Therapeutics shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Quince Therapeutics presently has a consensus price target of $65.00, suggesting a potential upside of 5,408.47%. CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 299.20%. Given Quince Therapeutics' higher probable upside, equities research analysts plainly believe Quince Therapeutics is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

CNS Pharmaceuticals' return on equity of -164.56% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
CNS Pharmaceuticals	N/A	-164.56%	-130.05%

Summary

Quince Therapeutics beats CNS Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

How does CNS Pharmaceuticals compare to Pasithea Therapeutics?

CNS Pharmaceuticals (NASDAQ:CNSP) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, risk, earnings, media sentiment, valuation and institutional ownership.

Pasithea Therapeutics' return on equity of -85.48% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CNS Pharmaceuticals	N/A	-164.56%	-130.05%
Pasithea Therapeutics	N/A	-85.48%	-77.42%

In the previous week, CNS Pharmaceuticals had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for CNS Pharmaceuticals and 1 mentions for Pasithea Therapeutics. Pasithea Therapeutics' average media sentiment score of 1.87 beat CNS Pharmaceuticals' score of 1.06 indicating that Pasithea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
CNS Pharmaceuticals	Positive
Pasithea Therapeutics	Very Positive

CNS Pharmaceuticals currently has a consensus price target of $20.00, suggesting a potential upside of 299.20%. Pasithea Therapeutics has a consensus price target of $3.00, suggesting a potential upside of 277.74%. Given CNS Pharmaceuticals' stronger consensus rating and higher probable upside, equities analysts clearly believe CNS Pharmaceuticals is more favorable than Pasithea Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than CNS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$41.30	N/A
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A

14.0% of CNS Pharmaceuticals shares are held by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are held by institutional investors. 0.0% of CNS Pharmaceuticals shares are held by company insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

CNS Pharmaceuticals has a beta of 2.62, indicating that its share price is 162% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Summary

CNS Pharmaceuticals beats Pasithea Therapeutics on 7 of the 13 factors compared between the two stocks.

Get CNS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CNSP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CNSP vs. The Competition

Export

Metric	CNS Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$4.48M	$3.42B	$6.34B	$12.37B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	-0.12	18.47	20.66	25.63
Price / Sales	N/A	294.84	547.76	76.59
Price / Cash	N/A	125.29	43.26	56.33
Price / Book	0.69	6.93	9.88	6.97
Net Income	-$15.85M	$24.11M	$3.55B	$333.62M
7 Day Performance	-31.28%	5.89%	1.69%	1.09%
1 Month Performance	82.18%	-0.91%	0.48%	3.08%
1 Year Performance	-66.87%	74.58%	39.39%	35.68%

CNS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CNSP CNS Pharmaceuticals	3.5685 of 5 stars	$5.01 -9.2%	$20.00 +299.2%	-63.7%	$4.48M	N/A	N/A	5	News Coverage Earnings Report Upcoming Earnings Gap Down
PTPI Petros Pharmaceuticals	N/A	$0.01 +9.2%	N/A	-95.1%	$221K	$5.11M	N/A	20	Gap Up
XCUR Exicure	1.0406 of 5 stars	$3.24 -4.1%	N/A	-70.2%	$21.54M	$500K	N/A	50
TRAW Traws Pharma	4.1355 of 5 stars	$1.68 -16.8%	$8.00 +376.2%	+31.5%	$20.52M	$2.79M	2.17	17	Earnings Report
QNCX Quince Therapeutics	2.8444 of 5 stars	$1.26 +1.6%	$65.00 +5,058.7%	-86.0%	$20.21M	N/A	N/A	60	News Coverage Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CNSP) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, XCUR, TRAW, QNCX, and KTTA

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Summary

How does CNS Pharmaceuticals compare to Exicure?

Summary

How does CNS Pharmaceuticals compare to Traws Pharma?

Summary

How does CNS Pharmaceuticals compare to Quince Therapeutics?

Summary

How does CNS Pharmaceuticals compare to Pasithea Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

CNS Pharmaceuticals (CNSP) Competitors

CNSP vs. PTPI, XCUR, TRAW, QNCX, and KTTA

How does CNS Pharmaceuticals compare to Petros Pharmaceuticals?

Do institutionals and insiders have more ownership in CNSP or PTPI?

Does the media prefer CNSP or PTPI?

Do analysts recommend CNSP or PTPI?

Which has more risk & volatility, CNSP or PTPI?

Which has preferable valuation and earnings, CNSP or PTPI?

Is CNSP or PTPI more profitable?

Summary

How does CNS Pharmaceuticals compare to Exicure?

Does the media favor XCUR or CNSP?

Which has higher earnings & valuation, XCUR or CNSP?

Do analysts rate XCUR or CNSP?

Do insiders & institutionals hold more shares of XCUR or CNSP?

Is XCUR or CNSP more profitable?

Which has more risk & volatility, XCUR or CNSP?

Summary

How does CNS Pharmaceuticals compare to Traws Pharma?

Does the media favor TRAW or CNSP?

Which has stronger earnings and valuation, TRAW or CNSP?

Do analysts recommend TRAW or CNSP?

Do institutionals & insiders hold more shares of TRAW or CNSP?

Which has more volatility and risk, TRAW or CNSP?

Is TRAW or CNSP more profitable?

Summary

How does CNS Pharmaceuticals compare to Quince Therapeutics?

Does the media favor QNCX or CNSP?

Which has more volatility and risk, QNCX or CNSP?

Which has stronger earnings and valuation, QNCX or CNSP?

Do institutionals & insiders hold more shares of QNCX or CNSP?

Do analysts recommend QNCX or CNSP?

Is QNCX or CNSP more profitable?

Summary

How does CNS Pharmaceuticals compare to Pasithea Therapeutics?

Is CNSP or KTTA more profitable?

Does the media refer more to CNSP or KTTA?

Do analysts prefer CNSP or KTTA?

Which has preferable valuation and earnings, CNSP or KTTA?

Do insiders and institutionals hold more shares of CNSP or KTTA?

Which has more volatility and risk, CNSP or KTTA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CNSP vs. The Competition

CNS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools